64th ASH Annual Meeting and Exposition: 114. Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological: Women's and Clinical Issues

Symposia: Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological Oral and Poster Abstracts
Oral

Research, Bleeding and Clotting, Sickle Cell Disease, adult, Non-Biological therapies, Sickle Cell Trait, epidemiology, Clinical Research, Genetic Disorders, health outcomes research, Hemoglobinopathies, thromboembolism, Diseases, Therapies, real-world evidence, pregnant, registries, young adult , Study Population, Human, Maternal Health

278-282 (Ernest N. Morial Convention Center)

Moderators:

Marquita Nelson, MD, MS, University of Tennessee Health Science Center and Giovanna Russo, Azienda Policlinico-Vittorio Emanuele, University of Catania

Disclosures:

Russo: Amgen, advisory board, Immune Thrombocytopenia: Membership on an entity's Board of Directors or advisory committees; Junia Pharma, speaker at webinar, Iron deficiency anemia: Speakers Bureau; Novartis, advisory Board, Immune Thrombocytopenia: Membership on an entity's Board of Directors or advisory committees; Grifols, advisory board, Immune Thrombocytopenia: Membership on an entity's Board of Directors or advisory committees.

This session will include new research related to clinical issues in sickle cell disease, with emphasis on women's health.

2:45 PM

805

Hormonal Contraceptive Use and Association with Thromboembolism in Women with Sickle Cell Disease

Natasha Bala, MD¹, Joseph R Stanek, MS²^*, Sara K. Vesely, PhD, MPH³, Robert M Cronin, MD, MS⁴, Susan E. Creary, MD, MSc⁵, Andrea H. Roe, MD, MPH⁶^*, Wendy Xu, PhD⁷^* and Sarah H. o'Brien, MD⁸

¹Nationwide Children's Hospital, Columbus, OH
²Division of Biostatistics, Nationwide Children's Hospital, Columbus, OH
³Biostatistics and Epidemiology, Hudson College of Public Health, The Univ. of OK Health Sciences Ctr., Oklahoma City, OK
⁴Department of Internal Medicine, The Ohio State University, Hilliard, OH
⁵Center for Innovation in Pediatric Practice, Division of Pediatric Hematology/Oncology/BMT, Nationwide Children's Hospital, Columbus, OH
⁶Department of Obstetrics and Gynecology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA
⁷Division of Health Services Management and Policy, The Ohio State University, Columbus, OH
⁸Division of Hematology/Oncology/BMT, Nationwide Children's Hospital, Columbus, OH

3:00 PM

806

Sickle Cell Disease-Specific Blood Pressure Thresholds for Hypertensive Disorders of Pregnancy: A Multinational Study

Macy L. Early, BA¹, A. Kinga Malinowski, MD, MSc, FRCSC², Marissa Solow, MD³^*, Ahizechukwu Eke, MBChB, PhD^4,5^*, Sana Saif Ur Rehman, MD⁶^*, Nadine Shehata, MD, FRCPC, MSc^7,8, Kevin H.M. Kuo, MD, MSc, FRCPC^9,10,11 and Lydia H. Pecker, MD¹²

¹Division of Hematology, Department of Medicine, Johns Hopkins Hospital, Baltimore, MD
²Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Mt. Sinai Hospital, Toronto, ON, CAN
³University Health Network, Toronto, ON, Canada
⁴Division of Clinical Pharmacology, Johns Hopkins School of Medicine, Baltimore, MD
⁵Division of Maternal-Fetal Medicine, Department of Gynecology & Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD
⁶Division of Hematology, Washington University School of Medicine, Saint Louis, MO
⁷Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
⁸Mount Sinai Hospital, Toronto, ON, Canada
⁹Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
¹⁰Division of Hematology, Department of Medicine, University of Toronto, Toronto, ON, Canada
¹¹Division of Medical Oncology and Hematology, Department of Medicine, University Health Network, Toronto, ON, Canada
¹²Division of Hematology, Department of Medicine, Johns Hopkins Medicine, Baltimore, MD

3:15 PM

807

Real-World Effectiveness of Voxelotor for the Treatment of Sickle Cell Disease: Group and Pediatric Subgroup Analyses of Effects on Transfusions, Vaso-Occlusive Crises, and Hospitalizations

Nirmish Shah, MD¹, Thokozeni Lipato, MD²^*, Thomas E. Delea, MSIA³^*, Alexander Lonshteyn, PhD³^*, Derek Weycker, PhD³^*, Andy Nguyen, PhD⁴^*, Anne Beaubrun, PhD⁴^* and Ofelia A. Alvarez, MD⁵

¹Duke University School of Medicine, Durham, NC
²Virginia Commonwealth University Health, Richmond, VA
³Policy Analysis Inc. (PAI), Brookline, MA
⁴Global Blood Therapeutics, South San Francisco, CA
⁵University of Miami Health System, Miami, FL

3:30 PM

808

Sickle Cell Disease Patients Mount Adequate Humoral but Reduced Cellular Responses to COVID-19 Vaccination

Cilia R. Pothast¹^*, Quincy Hofsink^2,3^*, Sabine Haggenburg^2,4^*, Michel Bhoekhan, BSc^2,3^*, Nienke J.E. Haverkate, BSc^3,5^*, Romy C. Dijkland, MSc¹^*, Kayleigh van Dijk, BSc¹^*, Frederik J.H. Falkenburg, MD, PhD¹, Annoek E.C. Broers, MD, PhD⁶^*, Jaap van Doesum, MD⁷^*, Robert S. van Binnendijk, PhD⁸^*, Gerco den Hartog, PhD⁸^*, Judith A. Burger, BSc⁹^*, Joey H. Bouhuijs, BSc⁹^*, Birgit I. Lissenberg-Witte, PhD¹⁰^*, Gaby P. Smits, MSc¹¹^*, Dorine Wouters, PhD¹²^*, Ester M.M. van Leeuwen, PhD^3,5,13^*, Hetty J. Bontkes, PhD^3,13^*, Neeltje A. Kootstra, PhD^3,5^*, Sonja Zweegman, MD, PhD^14,15, Arnon P. Kater, MD, PhD^2,15, Kaz Groen, MD¹⁶^*, Tom van Meerten, MD, PhD¹⁷^*, Pim G.N.J. Mutsaers⁶^*, Tim Beaumont, PhD¹⁸^*, Marit J. van Gils, PhD¹⁸^*, Abraham Goorhuis, MD, PhD¹⁹^*, Mette D. Hazenberg, MD, PhD^2,3,15,20^*, Inger S. Nijhof, MD, PhD^15,16,21^*, Mirjam H.M. Heemskerk¹ and Caroline E. Rutten, MD, PhD²^*

¹Department of Hematology, Leiden University Medical Center, Leiden, Netherlands
²Department of Hematology, Amsterdam UMC location University of Amsterdam, Amsterdam, Netherlands
³Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Amsterdam, Netherlands
⁴Amsterdam Institute of Infection and Immunity, Amsterdam UMC, Amsterdam, Netherlands
⁵Department of Experimental Immunology, Amsterdam UMC location University of Amsterdam, Amsterdam, Netherlands
⁶Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
⁷Department of Hematology, University Medical Center Groningen, Amsterdam, Netherlands
⁸Centre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment, Bilthoven, Netherlands
⁹Department of Medical Microbiology and Infection Prevention, Amsterdam UMC location University of Amsterdam, Amsterdam, Netherlands
¹⁰Department of Epidemiology and Data Science, Amsterdam UMC location Vrije Universiteit, Amsterdam, Netherlands
¹¹Centre for Immunology of Infectious Diseases and Vaccines, National Institute For Public Health and the Environment, Bilthoven, Netherlands
¹²Central Diagnostic Laboratory, Amsterdam UMC, Amsterdam, Netherlands
¹³Laboratory Medical Immunology, Amsterdam UMC, Amsterdam, Netherlands
¹⁴Department of Hematology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, Netherlands
¹⁵Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, Netherlands
¹⁶Department of Hematology, Amsterdam UMC location Vrije Universiteit, Amsterdam, Netherlands
¹⁷Department of Hematology, University Medical Center Groningen, Groningen, DC, Netherlands
¹⁸Department of Medical Microbiology and Infection Prevention, Amsterdam UMC, Amsterdam, Netherlands
¹⁹Department of Infectious Diseases, Amsterdam UMC location University of Amsterdam, Amsterdam, Netherlands
²⁰Department of Hematopoiesis, Sanquin Research, Amsterdam, Netherlands
²¹Department of Internal Medicine-Hematology, St. Antonius Hospital, Nieuwegein, Netherlands

3:45 PM

809

Examining Sickle Cell Trait Associated Clinical Outcomes in the All of Us research Program

Faeben Wossenseged, BS¹^*, Hasmin C Ramirez, MPH¹^*, Ashley J Buscetta, MSN, FNP-BC, CWOCN¹^*, Rakhi P. Naik, MD, MHS² and Vence L Bonham, JD¹

¹National Human Genome Research Institute, NIH, Bethesda, MD
²Division of Hematology, Johns Hopkins University, Baltimore, MD

4:00 PM

810

Association of Sickle Cell Trait and Venous Thromboembolism in the 23andMe Cohort

Keng-Han Lin, PhD¹^*, Julie M. Granka, PhD¹^*, Anjali Shastri, PhD¹^*, 23andMe Research Team¹^*, Vence L Bonham, JD² and Rakhi P. Naik, MD, MHS³

¹23andMe, Sunnyvale, CA
²National Human Genome Research Institute, Social and Behavioral Research Branch, National Institutes of Health, Bethesda, MD
³Division of Hematology, Department of Medicine, Johns Hopkins University, Baltimore, MD

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

114.O4.6 114. Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological: Women's and Clinical Issues